AR019818A1 - Un inmunoconjugado de miostatina. - Google Patents
Un inmunoconjugado de miostatina.Info
- Publication number
- AR019818A1 AR019818A1 ARP990100671A ARP990100671A AR019818A1 AR 019818 A1 AR019818 A1 AR 019818A1 AR P990100671 A ARP990100671 A AR P990100671A AR P990100671 A ARP990100671 A AR P990100671A AR 019818 A1 AR019818 A1 AR 019818A1
- Authority
- AR
- Argentina
- Prior art keywords
- myostatin
- peptide
- demiostatin
- multimer
- miostatina
- Prior art date
Links
- 108010056852 Myostatin Proteins 0.000 abstract 7
- 102000004472 Myostatin Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un péptido de miostatina que comprende por lo menos un epítope de miostatina, en donde el péptido comprende de al menos 3 aminoácidos contiguos demiostatina pero menor que la longitud completa de miostatina, un péptido de miostatina, un multímero demiostatina, un inmunoconjugado de miostatina, unacomposicion de vacuna, un polinucleotido, un vector recombinante, una célula huésped, un método para producir un multímero o péptido de miostatina, unanticuerpo aislado y el uso de los mismos para laf abricacion de un medicamento util para el tratamiento de una amplia variedad de desordenes y reducir laactividad de miostatina en sujetos vertebrados.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7521398P | 1998-02-19 | 1998-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR019818A1 true AR019818A1 (es) | 2002-03-20 |
Family
ID=22124285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990100671A AR019818A1 (es) | 1998-02-19 | 1999-02-23 | Un inmunoconjugado de miostatina. |
Country Status (18)
Country | Link |
---|---|
US (2) | US6369201B1 (es) |
EP (3) | EP1056845B1 (es) |
JP (1) | JP2002504326A (es) |
KR (1) | KR20010041111A (es) |
AR (1) | AR019818A1 (es) |
AT (2) | ATE352619T1 (es) |
AU (1) | AU765014B2 (es) |
BR (1) | BR9907995A (es) |
CA (2) | CA2687533C (es) |
CY (2) | CY1108074T1 (es) |
DE (2) | DE69934970T2 (es) |
DK (2) | DK1770162T3 (es) |
ES (3) | ES2280115T3 (es) |
IL (1) | IL137831A0 (es) |
NZ (1) | NZ506911A (es) |
PT (2) | PT1770162E (es) |
WO (1) | WO1999042573A1 (es) |
ZA (1) | ZA991369B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7566768B1 (en) * | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
MXPA01007366A (es) * | 1999-01-21 | 2002-06-04 | Metamorphix Inc | Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos. |
EA005248B1 (ru) * | 1999-07-20 | 2004-12-30 | Фармекса А/С | Способ отрицательной регуляции активности gdf-8 |
ZA200003786B (en) | 1999-07-30 | 2002-01-21 | Pfizer Prod Inc | Myostatin regulatory region, nucleotide sequence determination and methods for its use. |
WO2001053350A1 (en) * | 2000-01-18 | 2001-07-26 | Agresearch Limited | Myostatin and mimetics thereof |
US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
PL374966A1 (en) * | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
CA2476887A1 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Gasp1:a follistatin domain containing protein |
JP2006507356A (ja) * | 2002-09-16 | 2006-03-02 | ワイエス | ミオスタチンのメタロプロテアーゼ活性化およびミオスタチン活性の調節方法 |
AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
US7511012B2 (en) * | 2002-12-20 | 2009-03-31 | Amgen Inc. | Myostatin binding agents |
UA85055C2 (ru) | 2003-06-02 | 2008-12-25 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
KR20060120229A (ko) * | 2003-12-31 | 2006-11-24 | 쉐링-프라우 리미티드 | 중화 에피토프계 성장 증진 백신 |
JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
US20060034831A1 (en) * | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
CA2582940A1 (en) | 2004-09-30 | 2006-04-06 | Orico Limited | Myostatin isoform |
CA2594276A1 (en) * | 2004-12-30 | 2006-07-13 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
NZ538097A (en) * | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
CN101137906A (zh) * | 2005-03-23 | 2008-03-05 | 惠氏公司 | 对gdf-8调节剂的免疫应答的检测 |
JP2009518422A (ja) * | 2005-12-06 | 2009-05-07 | アムジェン インコーポレイテッド | ミオスタチン・アンタゴニストの使用 |
AU2013231037B2 (en) * | 2006-08-03 | 2016-05-12 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
AU2007279456A1 (en) * | 2006-08-03 | 2008-02-07 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
AU2007292555B2 (en) | 2006-09-05 | 2012-05-31 | Eli Lilly And Company | Anti-myostatin antibodies |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
JP2010535708A (ja) | 2007-08-03 | 2010-11-25 | ビオマリン アイジーエー リミテッド | デュシェンヌ型筋ジストロフィーの治療のための薬物併用 |
KR100857861B1 (ko) * | 2007-10-15 | 2008-09-11 | 주식회사 바이오리더스 | Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물 |
PT2880053T (pt) | 2012-08-01 | 2020-05-22 | Ikaika Therapeutics Llc | Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4 |
CN104391628B (zh) * | 2014-04-02 | 2018-02-23 | 贵阳朗玛信息技术股份有限公司 | 进程切换方法及装置 |
EP2960653A1 (en) * | 2014-06-24 | 2015-12-30 | Stichting Kwaliteitsgarantie Vleeskalversector | Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal |
EP3897689A1 (en) | 2018-12-21 | 2021-10-27 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
CN113474013B (zh) * | 2019-03-01 | 2024-06-21 | 神户天然物化学株式会社 | 肌肉生长抑制素剪接变体衍生蛋白对肌肉生长抑制素信号的抑制及其利用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1605763A (en) | 1926-11-02 | Garment retainer | ||
US2754818A (en) | 1950-06-24 | 1956-07-17 | Scherer Corp R P | Hypo jet injector |
US3330276A (en) | 1963-10-07 | 1967-07-11 | Scherer Corp R P | Hypodermic jet injector |
US3788315A (en) | 1971-04-20 | 1974-01-29 | S Laurens | Disposable cutaneous transjector |
US3853125A (en) | 1971-10-05 | 1974-12-10 | W Clark | Disposable needleless injector |
US4491632A (en) | 1979-10-22 | 1985-01-01 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
US4310550A (en) | 1979-10-26 | 1982-01-12 | Pfizer Inc. | Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants |
US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
DE3167442D1 (en) | 1980-07-07 | 1985-01-10 | Nat Res Dev | Improvements in or relating to cell lines |
US4341761A (en) | 1980-07-25 | 1982-07-27 | E. I. Du Pont De Nemours And Company | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon |
US4466917A (en) | 1981-02-12 | 1984-08-21 | New York University | Malaria vaccine |
US4493890A (en) | 1981-03-23 | 1985-01-15 | Miles Laboratories, Inc. | Activated apoglucose oxidase and its use in specific binding assays |
JPS5873993U (ja) | 1981-11-12 | 1983-05-19 | 三菱電機株式会社 | 2気筒回転式圧縮機 |
US4399121A (en) | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
US4427783A (en) | 1981-12-14 | 1984-01-24 | Hoffmann-La Roche Inc. | Immunoassay of thymosin α1 |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US4518385A (en) | 1983-06-13 | 1985-05-21 | Preci-Tech Ltd. | Disposable syringe for needleless injector |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
US5055400A (en) | 1986-11-26 | 1991-10-08 | University Of Guelph | Leukotoxin gene of pasteurella haemolytica |
US4957739A (en) | 1987-08-13 | 1990-09-18 | Board Of Regents, The University Of Texas System | Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever |
US5151267A (en) | 1988-07-15 | 1992-09-29 | University Of Saskatchewan | Bovine herpesvirus type 1 polypeptides and vaccines |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
CA2014033C (en) | 1989-04-07 | 1993-02-09 | Stephen D. Acres | Compositions and treatments for pneumonia in animals |
US5062830A (en) | 1990-04-04 | 1991-11-05 | Derata Corporation | Dry disposable nozzle assembly for medical jet injector |
US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
US5837268A (en) | 1991-10-16 | 1998-11-17 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
ES2251721T3 (es) | 1994-07-08 | 2006-05-01 | The Johns Hopkins University School Of Medicine | Factor-11 de diferenciacion del crecimiento. |
WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
DE69841139D1 (de) | 1997-07-14 | 2009-10-22 | Univ Liege | Mutationen im myostatingen steigern muskelmasse in säugetieren |
AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
WO1999024618A1 (en) | 1997-11-10 | 1999-05-20 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
CA2319703C (en) | 1998-02-05 | 2005-09-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
EA005248B1 (ru) | 1999-07-20 | 2004-12-30 | Фармекса А/С | Способ отрицательной регуляции активности gdf-8 |
-
1999
- 1999-02-18 US US09/252,149 patent/US6369201B1/en not_active Expired - Lifetime
- 1999-02-19 AU AU25073/99A patent/AU765014B2/en not_active Ceased
- 1999-02-19 KR KR1020007009152A patent/KR20010041111A/ko not_active Application Discontinuation
- 1999-02-19 DK DK06026306T patent/DK1770162T3/da active
- 1999-02-19 ES ES99904660T patent/ES2280115T3/es not_active Expired - Lifetime
- 1999-02-19 WO PCT/CA1999/000128 patent/WO1999042573A1/en active IP Right Grant
- 1999-02-19 CA CA2687533A patent/CA2687533C/en not_active Expired - Lifetime
- 1999-02-19 PT PT06026306T patent/PT1770162E/pt unknown
- 1999-02-19 DE DE69934970T patent/DE69934970T2/de not_active Expired - Lifetime
- 1999-02-19 ES ES06026306T patent/ES2318654T3/es not_active Expired - Lifetime
- 1999-02-19 JP JP2000532513A patent/JP2002504326A/ja active Pending
- 1999-02-19 DE DE69940230T patent/DE69940230D1/de not_active Expired - Lifetime
- 1999-02-19 EP EP99904660A patent/EP1056845B1/en not_active Expired - Lifetime
- 1999-02-19 DK DK99904660T patent/DK1056845T3/da active
- 1999-02-19 NZ NZ506911A patent/NZ506911A/en not_active IP Right Cessation
- 1999-02-19 PT PT99904660T patent/PT1056845E/pt unknown
- 1999-02-19 CA CA002323607A patent/CA2323607C/en not_active Expired - Fee Related
- 1999-02-19 AT AT99904660T patent/ATE352619T1/de active
- 1999-02-19 ZA ZA9901369A patent/ZA991369B/xx unknown
- 1999-02-19 ES ES08018446.8T patent/ES2527410T3/es not_active Expired - Lifetime
- 1999-02-19 EP EP08018446.8A patent/EP2018871B1/en not_active Expired - Lifetime
- 1999-02-19 AT AT06026306T patent/ATE419353T1/de active
- 1999-02-19 EP EP06026306A patent/EP1770162B1/en not_active Expired - Lifetime
- 1999-02-19 BR BR9907995-0A patent/BR9907995A/pt active Search and Examination
- 1999-02-19 IL IL13783199A patent/IL137831A0/xx unknown
- 1999-02-23 AR ARP990100671A patent/AR019818A1/es active IP Right Grant
-
2002
- 2002-02-11 US US10/074,152 patent/US20030065137A1/en not_active Abandoned
-
2007
- 2007-04-23 CY CY20071100550T patent/CY1108074T1/el unknown
-
2009
- 2009-03-18 CY CY20091100304T patent/CY1108889T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR019818A1 (es) | Un inmunoconjugado de miostatina. | |
DE69006628D1 (de) | Pharmazeutische Zusammensetzung, enthaltend Loratadin, Ibuprofen und Pseudoephedrin. | |
CO5011037A1 (es) | Metodo para mejorar la condicion de la piel de un usuario en el area cubierta por un articulo absorbente | |
BR9909110A (pt) | Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo | |
ES2150496T3 (es) | Cicloalquilimidazopiridinas condensadas. | |
ITRM940621A0 (it) | "composizione farmaceutica stabilizzata, relativo solvente e procedimento di preparazione" | |
LU91342I2 (fr) | Byetta-exénatide | |
DK0695171T3 (da) | Lyosfærer indeholdende gonadotropin | |
IT1279109B1 (it) | Procedimento per il riconoscimento di difetti nell'ispezione di superfici strutturate. | |
DZ1763A1 (fr) | Composition vaccinantes. | |
IT1267448B1 (it) | Vaccino per la prevenzione della sindrome riproduttiva e respiratoria porcina. | |
NO902280L (no) | Ny poroes farmasoeytisk form og fremstilling derav. | |
DE69932510D1 (de) | Vaskularisierungsinhibitoren | |
BR9810907A (pt) | Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico | |
BR9803756A (pt) | Polimento da unha antipsoriático. | |
DK0470117T3 (da) | Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner | |
AR003589A1 (es) | Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido. | |
AR002949A1 (es) | Análogos del peptido p277 y composiciónes farmaceuticas y preparaciónes que los comprenden para el tratamiento o diagnostico de diabetes y un equipo para diagnosticar. | |
DE69420145D1 (de) | Behandlung präkanzeröser läsionen durch muramylpeptide | |
BR9812363A (pt) | Composição de dentifrìcio anticárie com diversos componentes, e, processo de remineralização de porções desmineralizadas das estruturas dentais | |
ES2118939T3 (es) | Peptido para el diagnostico e inmunizacion contra la infeccion con t.cruzi. | |
BR9709406B1 (pt) | fluorenonas alquiloxiamino substituìdas e composição farmacêutica contendo as mesmas. | |
ES2183814T3 (es) | Composicion farmaceutica que contiene il-6 y su uso para el tratamiento del trastorno trombohemorragico de consumo. | |
ES2171453T3 (es) | Metodo de fabricacion de una barrera alargada. | |
ES2308850T3 (es) | Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |